Literature DB >> 16806744

Repetitive exposure to TGF-beta suppresses TGF-beta type I receptor expression by differentiated osteoblasts.

Kenneth K Kim1, Changhua Ji, Weizhong Chang, Rebecca G Wells, Caren M Gundberg, Thomas L McCarthy, Michael Centrella.   

Abstract

Transforming growth factor-beta (TGF-beta) has potent, cell phenotype restricted effects. In bone, it controls multiple activities by osteoblasts through three predominant receptors. Of these, the relative amounts of TGF-beta receptor I (TbetaRI) vary directly with TGF-beta sensitivity. The rat TbetaRI gene promoter includes cis-acting elements for transcription factor Runx2. Here we show conservation and selective partitioning of TbetaRI and retention of TGF-beta activity with osteoblast differentiation, Runx2 binding to the TbetaRI gene promoter on osteoblast chromatin, and decreased promoter activity by Runx2 binding site mutation. Furthermore, in contrast to the stimulatory effects induced by single or limited exposure to TGF-beta, we found that osteoblasts became resistant to TGF-beta after high dose and repetitive treatment. TbetaRI protein, mRNA, and gene promoter activity all decreased after three daily TGF-beta treatments, in parallel with a reduction in Runx2 protein and Runx dependent gene expression. In this way, sustained TGF-beta exposure can limit its own effectiveness by suppressing the expression of its primary signaling receptor. This tightly controlled system may constitute a feedback loop to protect against TGF-beta excess, and impose important limitations that are required for the progression of events during skeletal growth, remodeling and repair.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16806744     DOI: 10.1016/j.gene.2006.05.005

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  8 in total

Review 1.  TGF-β Family Signaling in Mesenchymal Differentiation.

Authors:  Ingo Grafe; Stefanie Alexander; Jonathan R Peterson; Taylor Nicholas Snider; Benjamin Levi; Brendan Lee; Yuji Mishina
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-05-01       Impact factor: 10.005

2.  Stratified control of IGF-I expression by hypoxia and stress hormones in osteoblasts.

Authors:  Thomas L McCarthy; Zhong Yun; Joseph A Madri; Michael Centrella
Journal:  Gene       Date:  2014-01-15       Impact factor: 3.688

3.  β-Catenin independent cross-control between the estradiol and Wnt pathways in osteoblasts.

Authors:  Thomas L McCarthy; Caleb B Kallen; Michael Centrella
Journal:  Gene       Date:  2011-02-16       Impact factor: 3.688

4.  Novel links among Wnt and TGF-beta signaling and Runx2.

Authors:  Thomas L McCarthy; Michael Centrella
Journal:  Mol Endocrinol       Date:  2010-01-21

5.  Expression of Runx2 transcription factor in non-skeletal tissues, sperm and brain.

Authors:  Jae-Hwan Jeong; Jung-Sook Jin; Hyun-Nam Kim; Sang-Min Kang; Julie C Liu; Christopher J Lengner; Florian Otto; Stefan Mundlos; Janet L Stein; Andre J van Wijnen; Jane B Lian; Gary S Stein; Je-Yong Choi
Journal:  J Cell Physiol       Date:  2008-11       Impact factor: 6.384

6.  Role of TGF-β1 in Fluoride-Treated Osteoblasts at Different Stages.

Authors:  Ningning Jiang; Wenshu Xu; Zhongyuan Zhang; Hui Jin; Yang Yang; Jingmin Zhang; Hui Xu
Journal:  Biol Trace Elem Res       Date:  2021-05-24       Impact factor: 3.738

7.  Modulation of transforming growth factor beta signalling pathway genes by transforming growth factor beta in human osteoarthritic chondrocytes: involvement of Sp1 in both early and late response cells to transforming growth factor beta.

Authors:  Catherine Baugé; Olivier Cauvard; Sylvain Leclercq; Philippe Galéra; Karim Boumédiene
Journal:  Arthritis Res Ther       Date:  2011-02-15       Impact factor: 5.156

8.  Proliferating and differentiating effects of three different growth factors on pluripotent mesenchymal cells and osteoblast like cells.

Authors:  Britt Wildemann; Nicole Burkhardt; Marc Luebberstedt; Thomas Vordemvenne; Gerhard Schmidmaier
Journal:  J Orthop Surg Res       Date:  2007-12-20       Impact factor: 2.359

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.